SCHEMBL5541641

SCHEMBL5541641

Clc1ccc([CH]c2cc[nH]n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.37
AHR P35869 1/20 0.33
MAOB P27338 1/20 0.33
GAA P10253 2/20 0.33
F7 P08709 1/20 0.32
F3 P13726 1/20 0.32
DYRK1A Q13627 1/20 0.32
LMNA P02545 2/20 0.32
CYP2A6 P11509 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
AMY1A P0DUB6 1/20 0.32
CYP1A2 P05177 2/20 0.31
GSK3B P49841 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
HAO1 Q9UJM8 1/20 0.31
ALDH1A1 P00352 2/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544142 0.80 CYP2A6 (0.32) HSD17B10MAOBCYP2A6NPC1RAB9A
SCHEMBL5539084 0.80 NFE2L2 (0.34) GAAALDH1A1MAPT
SCHEMBL1176839 0.79 KMT2A (0.35) MAOBLMNACYP2A6KDM4ECYP1A2
SCHEMBL5540093 0.78 CHRM5 (0.43) MAOBCYP1A2PIM1PIM2MEN1
SCHEMBL20535558 0.78
SCHEMBL1202896 0.69 HSD17B10 (0.58) HSD17B10AHRMAOBLMNACYP2A6
SCHEMBL7923050 0.69 HSD17B10 (0.34) HSD17B10AHRMAOBGAAF7
SCHEMBL5713385 0.68 LMNA (0.33) LMNAKDM4ENPC1RAB9ACYP1A2
SCHEMBL5713386 0.68 LMNA (0.33) LMNAKDM4ENPC1RAB9ACYP1A2
SCHEMBL5535692 0.67 ALDH1A1 (0.44) MAOBGAAKDM4EPIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSD17B10 467/4885AHR 1471/4885MAOB 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.